132 related articles for article (PubMed ID: 22996774)
1. [Cisplatin administration for outpatients with short hydration of less than four hours].
Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
3. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
4. [The feasibility of CDDP administration for gastric cancer outpatients undergoing S-1/cisplatin combination therapy].
Kishimoto T; Imamura H; Kawabata R; Kimura Y; Fujii C; Fukunaga M; Ohzato H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2304-6. PubMed ID: 23268058
[TBL] [Abstract][Full Text] [Related]
5. [Safety Assessment of a Short Hydration Regimen for Outpatient Cisplatin-Based Chemotherapy].
Yoshida H; Kimata T; Suzuki M; Uchida T; Yamamuro O
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1081-5. PubMed ID: 27628548
[TBL] [Abstract][Full Text] [Related]
6. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Tohnai I; Kawabe Y; Nakashima T; Yamagiwa M; Suzuki T; Mizuno A; Mineda H
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2567-78. PubMed ID: 1702133
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
[TBL] [Abstract][Full Text] [Related]
10. [The histological antitumor effect and side effects of preoperative chemotherapy for patients with oral squamous cell carcinoma--comparison between low-dose and high-dose CDDP regimens].
Nakazawa M; Iwai S; Moriyama T; Kato I; Uekusa Y; Katagiri W; Takeuchi N; Matsumoto K; Sakuda M
Gan To Kagaku Ryoho; 2001 Mar; 28(3):337-43. PubMed ID: 11265401
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron].
Ikeda H; Koshiba R
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1947-53. PubMed ID: 9797818
[TBL] [Abstract][Full Text] [Related]
12. [Feasibility of S-1/CDDP therapy for outpatients with advanced gastric cancer].
Rino Y; Murakami H; Yukawa N; Wada N; Oshima T; Matsuura H; Sugano N; Arai H; Masuda M; Imada T
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1829-31. PubMed ID: 19920383
[TBL] [Abstract][Full Text] [Related]
13. Safe, rapid administration of cisplatin in the outpatient clinic.
Brock J; Alberts DS
Cancer Treat Rep; 1986 Dec; 70(12):1409-14. PubMed ID: 3539327
[TBL] [Abstract][Full Text] [Related]
14. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
16. [A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Kanamori N; Fujii M; Takahashi T; Wakabayashi K; Kochi M; Sou K; Takayama T
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1459-61. PubMed ID: 17876146
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
[TBL] [Abstract][Full Text] [Related]
18. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
19. [Definitive end-stage chronic kidney failure after cisplatin treatment].
Brillet G; Deray G; Lucsko M; Faucher C; Aubert P; Rottembourg J; Jacobs C
Nephrologie; 1993; 14(5):227-9. PubMed ID: 8159252
[TBL] [Abstract][Full Text] [Related]
20. Use of high-dose cisplatin with aprepitant in an outpatient setting.
Furukawa N; Kawaguchi R; Kobayashi H
Eur J Cancer Care (Engl); 2012 Jul; 21(4):436-41. PubMed ID: 21883567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
